OVID

Ovid Therapeutics Inc.

3.36 USD

Last updated Dec 10, 00:14 UTC

Yesterday HIGH

$3.44

Yesterday LOW

$3.34

52w HIGH

$4.14

52w LOW

$1.62

EPS

-0.16

PE

-21.00

Next Earnings

Mar 11, 2024

Overview News Insider Transactions Government Trades

Ovid Therapeutics Inc. stock is up 5.99% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 December’s closed higher than November.

Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

ovidrx.com

Benzinga Insights

Wed Mar 15, 2023

Looking Into Ovid Therapeutics's Return On Capital Employed
Benzinga Newsdesk

Mon Mar 13, 2023

Ovid Therapeutics' 2022 Cash, Cash Equivalents & Marketable Securities Of $129M; Cash Runway Expected Into 1H 2025
Benzinga Newsdesk

Mon Mar 13, 2023

Ovid Therapeutics Q4 EPS $(0.16) Beats $(0.18) Estimate, Sales $46.28K

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 57.89 percent increase over losses of $(0.38) per share from
Happy Mohamed

Wed Mar 8, 2023

Studies Published In Cell Reports Medicine Validate The Potential Of Direct KCC2 Activation In Resistant Seizures

OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal excitation, including epilepsies Two preclinical seizure models suggest that OV350
Benzinga Newsdesk

Thu Jan 5, 2023

Ovid Therapeutics Dosed Healthy Volunteers With OV329 In Phase 1 Trial
Benzinga Insights

Tue Nov 8, 2022

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 184 companies set new 52-week lows.
Benzinga Newsdesk

Tue Nov 8, 2022

Ovid Therapeutics Q3 EPS $(0.17), Same YoY

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share. This is unchanged from the same period last year.
Benzinga Insights

Mon Nov 7, 2022

Stocks That Hit 52-Week Lows On Monday

On Monday, 160 companies hit new 52-week lows.
Benzinga Insights

Wed Oct 12, 2022

Stocks That Hit 52-Week Lows On Wednesday

During Wednesday's trading, 517 companies set new 52-week lows.
Benzinga Insights

Tue Oct 11, 2022

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 838 companies hit new 52-week lows.